Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

China Medical Given SFDA Approval for SPR Diagnostic System

publication date: Oct 19, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

China Medical Technologies (中国医疗技术公司) reported it received SFDA approval for its Surface Plasmon Resonance (SPR) diagnostic technology, a molecular biology biosensor. China Medical Technologies has developed SPR as a diagnostic test for human papillomavirus (HPV), a common virus that causes warts and can ultimately cause cervical cancer. One year ago, China Medical paid a very substantial $345 million to acquire the technology. More details...

Stock Symbol: (NSDQ: CMED)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners